<DOC>
	<DOCNO>NCT00135551</DOCNO>
	<brief_summary>A number major clinical trial demonstrate clinical benefit lower blood pressure indicate majority patient hypertension require one drug achieve optimal blood pressure control . There little data show antihypertensive combination best protect patient cardiovascular event best achieves target blood pressure few adverse event . The COPE trial plan investigate , patient hypertension , combination antihypertensive drug , angiotensin receptor blocker , β-blockers thiazide diuretic addition long-acting calcium antagonist , benidipine hydrochloride , superior achieve target blood pressure prevent cardiovascular event few adverse drug effect .</brief_summary>
	<brief_title>Benidipine-based Comparison Angiotensin Receptors , β-blockers , Thiazide Diuretics Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Benidipine</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Outpatients require combination therapy sit systolic blood pressure ≥ 140 mmHg diastolic blood pressure ≥ 90 mmHg . Outpatients age 40 year less 85 year ( inclusive ) , regardless sex . Previously untreated patient patient therapy , convert 4mg benidipine . Patients treated benidipine , angiotensin receptor blocker , βblockers , thiazide diuretic . Seated systolic blood pressure ≥ 200 mmHg seat diastolic blood pressure ≥ 120 mmHg . Secondary hypertension . Type I diabetes mellitus type 2 diabetes insulin treatment . History cerebrovascular disorder , myocardial infarction , angina pectoris , coronary angioplasty coronary artery bypass graft surgery within 6 month prior enrolment study . Heart failure ( New York Heart Association [ NYHA ] functional classification II , III IV ) . Chronic atrial fibrillation atrial flutter . Congenital heart disease history rheumatic heart disease . Severe peripheral arterial disease ( Fontaine Class II , III IV ) . Serious liver dysfunction ( AST ALT ≥100 IU / l ) . Serious renal dysfunction ( serum creatinine ≥ 2mg/dl ) . History malignancy 5 year prior study entry . Pregnancy . Compliance rate &lt; 70 % assessed patient interview . Known hypersensitivity contraindication benidipine , angiotensin receptor blocker , βblockers , thiazide diuretic . Other serious illness significant abnormality investigator judge inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Multicenter clinical trial</keyword>
	<keyword>PROBE</keyword>
	<keyword>Combination therapy</keyword>
	<keyword>Benidipine</keyword>
	<keyword>Essential Hypertension</keyword>
</DOC>